Search results
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
Zacks via Yahoo Finance UK· 5 hours agoEli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi...
Why the weight-loss drug boom is just the beginning
LoveMONEY via Yahoo Finance UK· 1 day agoFind out how Ozempic, Mounjaro, and other medicines are helping to revolutionise weight loss around the world... and how much people are willing to pay...
Bankers Investment Trust: Why TSMC is a safer bet than Nvidia | Trustnet
TrustNet· 1 day agoGlobal stock markets have become obsessed with a narrow group of winners, such as chipmaker Nvidia and obesity drug manufacturers Novo Nordisk and Eli & ...
The curse of influencer publishing
The New Statesman· 2 days agoThe slow creep of influencer publishing – the rise of social media stars being handed fat advances and big marketing budgets for memoirs, self-help books...
A New Alzheimer’s Drug May Be the Most Effective One Yet
Time via Yahoo News UK· 2 days agoLilly is collaborating with Roche to make the test more available to doctors who can order it as a...
'New era' in Alzheimer's disease treatment as second drug approved in US
Irish Examiner· 2 days agoNew drug, which slowed cognitive and functional decline by up to 35% in trials, welcomed by...
If Not President Biden, Then Who?
New York Times· 2 days agoDemocrats and donors are pondering who could be the best alternative to take on Donald Trump after faltering attempts to calm nerves following last...
Revealed: the 103 professional lobbyists standing in the 2024 general election
The New Statesman· 3 days agoHanbury is a registered lobbying firm whose clients, during the time that Ward has been a director,...
InnovationRx: A Fourth Dairy Worker Has Contracted Avian Flu
Forbes· 3 days agoInnovationRx is your weekly digest of healthcare news. Today, the Colorado Department of Public...
Hormone Replacement Therapy Market Poised for Steady Growth, Forecasted to Reach USD 23,729.6 Millio
PharmiWeb· 3 days agoThe hormone replacement therapy market is set to experience steady growth, projecting a compound annual growth rate (CAGR) of 3.5% over the forecast period. A< ...
